Table 2.
Impact of AURKA and AURKB on chemo- and/or radiotherapy in lung cancer.
| Aurora Kinase | Effect on Chemo-and/or Radiotherapy | Experimental Sample; Method | Reference |
|---|---|---|---|
| AURKA | Resistance to EGFR inhibitors; triggers disease recurrence | EGFR-mutant lung adenocarcinoma cells; in vitro/in vivo analysis | [25] |
| AURKA | Overexpression confers resistance to radiotherapy in docetaxel-resistant, SPC-A1/DTX lung adenocarcinoma cells | SPC-A1 lung cancer cells; in vitro analysis | [50] |
| AURKA | AURKA/TPX2 overexpression associates with paclitaxel-mediated radiosensitization; improves OS | Cancer genome atlas lung adenocarcinoma cohort; in vitro analysis | [27] |
| AURKA | Resistance to gefitinib-induced apoptosis | A549 lung cancer cells: in vitro analysis | [26] |
| AURKA | Resistance to cytotoxic agents such as adriamycin and VP-16 (etoposide) | A549 lung cancer cells; in vitro analysis | [51,52] |
| AURKB | Resistance to EGFR inhibitors | NSCLC tumor samples; in vitro analysis | [1] |
| AURKB | Low levels confer resistance to paclitaxel | NSCLC cell lines; in vitro analysis | [45] |
Abbreviations: NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; SPC-A1, human lung cancer cell line; DTX, docetaxel; TPX2, targeting protein for Xklp2; OS, overall survival.